Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Change in Cash (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Change in Cash for 6 consecutive years, with -$7.3 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 238.27% to -$7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, up 424.5% year-over-year, with the annual reading at $2.6 million for FY2025, 424.5% up from the prior year.
  • Change in Cash hit -$7.3 million in Q4 2025 for Insight Molecular Diagnostics, down from -$5.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $51.8 million in Q1 2021 to a low of -$15.2 million in Q1 2022.
  • Historically, Change in Cash has averaged $203800.0 across 5 years, with a median of -$5.1 million in 2023.
  • Biggest YoY gain for Change in Cash was 1041.85% in 2021; the steepest drop was 5764.38% in 2021.
  • Year by year, Change in Cash stood at -$7.7 million in 2021, then plummeted by 36.39% to -$10.5 million in 2022, then surged by 58.76% to -$4.4 million in 2023, then soared by 221.19% to $5.3 million in 2024, then crashed by 238.27% to -$7.3 million in 2025.
  • Business Quant data shows Change in Cash for IMDX at -$7.3 million in Q4 2025, -$5.8 million in Q3 2025, and -$6.7 million in Q2 2025.